Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma

@inproceedings{Tannir2017CabozantinibAA,
  title={Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma},
  author={Nizar M. Tannir and Gisela M Schwab and Viktor Gr{\"u}nwald},
  booktitle={Current oncology reports},
  year={2017}
}
Clear cell renal cell carcinoma (RCC) is characterized by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL loss drives tumor angiogenesis and accounts for the clinical activity of VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs), the first-line standard of care for advanced RCC. Within the last year, three new second-line… CONTINUE READING